Fosun Pharma subsidiary gets approval for iron overload drugs

Shanghai Fosun Pharmaceutical Group (Fosun Pharma) announced that its controlled subsidiary, Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd., has received approval from the National Medical Products Administration for the registration of Deferasirox Tablets (90mg, 360mg) and Deferasirox Granules (360mg). These are classified as Class 3 chemical drugs and are indicated for chronic iron overload in patients with β-thalassemia and non-transfusion dependent thalassemia.

As of September 2025, the group's cumulative research and development investment for these drugs totaled approximately RMB 24.55 million. According to IQVIA CHPA data, sales of Deferasirox formulations in China (excluding Hong Kong, Macau, and Taiwan) reached approximately RMB 128 million in 2024.

The approval of these drugs will further enrich Fosun Pharma's product line. However, the company cautions investors that actual sales performance post-launch may be influenced by factors such as demand, market competition, and distribution channels, leading to inherent uncertainties.